Key Details
Price
$2.62Annual ROE
-71.09%Beta
1.20Events Calendar
Next earnings date:
Mar 26, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Mar 26, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
On Thursday, Vigil Neuroscience Inc. VIGL released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer's disease.
– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer's disease in 1Q 2025 –
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences.
NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - - Announced interim data from VG-3927 Phase 1 trial in healthy volunteers that support continued development as potential therapy for Alzheimer's disease - WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2024, and provided an update on recent progress.
WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations highlighting its oral small molecule VG-3927 at the 2024 Alzheimer's Association International Conference (AAIC) taking place on July 28-August 1, 2024 in Philadelphia, Pennsylvania and virtually.
NEW YORK , July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
Vigil Neuroscience (NASDAQ: VIGL ) stock is soaring higher on Thursday after the clinical-stage biotechnology company revealed a $40 million strategic investment from Sanofi (NASDAQ: SNY ). This investment has Sanofi purchasing 537,634 shares of Series A non-voting preferred shares at a price of $7.44 each.
LEUVEN, Belgium--(BUSINESS WIRE)-- #ALS--Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gemma Fri.
FAQ
- What is the ticker symbol for Vigil Neuroscience?
- Does Vigil Neuroscience pay dividends?
- What sector is Vigil Neuroscience in?
- What industry is Vigil Neuroscience in?
- What country is Vigil Neuroscience based in?
- When did Vigil Neuroscience go public?
- Is Vigil Neuroscience in the S&P 500?
- Is Vigil Neuroscience in the NASDAQ 100?
- Is Vigil Neuroscience in the Dow Jones?
- When was Vigil Neuroscience's last earnings report?
- When does Vigil Neuroscience report earnings?
- Should I buy Vigil Neuroscience stock now?